Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

TEVAR safe, acceptable for type B aortic dissection

14 Feb 2020

Thoracic endovascular aortic repair (TEVAR) is a feasible intervention for type B aortic dissection (type B AD) with an acceptable safety profile, a new meta-analysis reports.

Accessing the databases of PubMed, the Cochrane Library and Science-Direct, researchers retrieved 92 relevant studies, yielding a pooled cohort of 5,956 patients. The primary outcomes of the meta-analysis were in-hospital all-cause mortality and aorta-related mortality.

There were 262 cases of early mortality, all occurring within 30 days after TEVAR. The most common causes of death were aortic rupture (25.6 percent), retrograde type A aortic dissection (15.9 percent) and cardiac complications (15.3 percent).

The resulting pooled estimate for overall mortality was 7.0 percent (95 percent confidence interval [CI], 6.2–7.8). For aorta- or procedure-related mortality, the resulting estimate was 5.2 percent (95 percent CI, 4.4–6.0). In comparison, the pooled rates of stroke and spinal cord ischaemia were 4.2 percent (95 percent CI, 3.6–4.9) and 3.3 percent (95 percent CI, 2.8–3.9), respectively.

Thirty-three studies, with a pooled sample of 1,924 patients, were available for the assessment of early- and mid-term TEVAR outcomes. These showed that institutions with endovascular treatment case loads of at least 40 performed the intervention better and had lower rates of in-hospital and aorta-related mortality.

“TEVAR has gained popularity during the past two decades as a less invasive procedure with promising results. However, current optimal treatment of Stanford type B AD, especially for uncomplicated cases, remains controversial,” said researchers. The present study showed that such an intervention may be feasible.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.